A61K 47/6805
The drug being a vinca alkaloid
Official title: {the drug being a vinca alkaloid}
A61K47/6805 (The drug being a vinca alkaloid) appears on 35 US grants and 77 published applications in this corpus.
Search patents in A61K- Granted patents
- 35
- Published applications
- 77
- Assignees
- 47
- Inventors
- 182
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 4 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 1 | 1 |
| 2007 | 1 | 0 |
| 2008 | 0 | 6 |
| 2009 | 2 | 4 |
| 2010 | 1 | 0 |
| 2011 | 1 | 3 |
| 2012 | 2 | 1 |
| 2013 | 0 | 3 |
| 2014 | 3 | 1 |
| 2015 | 0 | 3 |
| 2016 | 1 | 3 |
| 2017 | 2 | 6 |
| 2018 | 1 | 1 |
| 2019 | 1 | 2 |
| 2020 | 2 | 3 |
| 2021 | 3 | 2 |
| 2022 | 0 | 3 |
| 2023 | 2 | 6 |
| 2024 | 1 | 10 |
| 2025 | 2 | 9 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for reducing off-target toxicity of antibody drug conjugates12 May 2026US 12,624,123 B2The Research Foundation for The State University of New York
- Anti-PTK7 antibody and uses thereof27 Jan 2026US 12,534,541 B2Mabcare Therapeutics
- Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof3 Jun 2025US 12,318,457 B2Genequantum Healthcare (Suzhou) Co., Ltd.
- Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class18 Feb 2025US 12,226,490 B2Sutro Biopharma, Inc.
- Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates19 Nov 2024US 12,144,869 B2Sutro Biopharma, Inc.
- Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies10 Sep 2026US 2026/0263622 A1
- Compositions and methods for reducing off-target toxicity of antibody drug conjugates3 Sep 2026US 2026/0258151 A1The Research Foundation for The State University of New York
- Methods of Treating Cancer Using Anti-HER2 Antibody-Drug Conjugates and HER2 Kinase Inhibitors27 Aug 2026US 2026/0248947 A1Seagen Inc.
- An antibody-drug conjugate having two or more functional small molecule compounds for enhanced treatment of refractory diseases16 Jul 2026US 2026/0199510 A1Hangzhou Dac Biotech Co., Ltd.
- Bcma monoclonal antibody and the antibody-drug conjugate11 Jun 2026US 2026/0158153 A1Hangzhou Dac Biotech Co., Ltd.
Most cited
By later US patents
- 27411, a novel human PGP synthase93US 7,029,895 B2Millennium Pharmaceuticals, Inc. · 2006
- Ubiquitin protease87US 7,482,147 B2Millennium Pharmaceuticals, Inc. · 2009
- Ubiquitin protease57US 7,776,577 B2Millennium Pharmaceuticals, Inc. · 2010
- Anti-IGF-IR antibodies and uses thereof56US 7,241,444 B2Pierre Fabre Medicament · 2007
- Conjugates of vinblastine, a process for their preparation and their use in therapy39US 4,870,162 AOmnichem · 1989